Literature DB >> 27125501

Liver: Asprosin - new hormone involved in hepatic glucose release.

Claire Greenhill.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27125501     DOI： 10.1038/nrendo.2016.66

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  1 in total

1.  Asprosin, a Fasting-Induced Glucogenic Protein Hormone.

Authors:  Chase Romere; Clemens Duerrschmid; Juan Bournat; Petra Constable; Mahim Jain; Fan Xia; Pradip K Saha; Maria Del Solar; Bokai Zhu; Brian York; Poonam Sarkar; David A Rendon; M Waleed Gaber; Scott A LeMaire; Joseph S Coselli; Dianna M Milewicz; V Reid Sutton; Nancy F Butte; David D Moore; Atul R Chopra
Journal:  Cell       Date:  2016-04-14       Impact factor: 41.582
  1 in total
  9 in total

1.  Saliva and Blood Asprosin Hormone Concentration Associated with Obesity.

Authors:  Kader Ugur; Suleyman Aydin
Journal:  Int J Endocrinol       Date:  2019-03-27       Impact factor: 3.257

2.  Increased Serum IGFBP-1 and Reduced Insulin Resistance After Roux-En-Y Gastric Bypass in Chinese Patients with Type 2 Diabetes: a 6-Month Follow-Up.

Authors:  Zhigao Song; Xiaojian Dai; Hao Yu; Qing Luo; Hongbin Zhang; Liangping Wu
Journal:  Obes Surg       Date:  2018-10       Impact factor: 4.129

3.  [Expression, purification and functional assessment of asprosin inclusion body].

Authors:  Xuejing Wei; Qingqing Ao; Ling Meng; Yilu Xu; Cailing Lu; Shen Tang; Xinhang Wang; Xiyi Li
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2020-01-30

4.  The serum level of irisin, but not asprosin, is abnormal in polycystic ovary syndrome patients.

Authors:  Chia Lin Chang; Shang Yu Huang; Ya Chiung Hsu; Tzu Hsuan Chin; Yung Kuei Soong
Journal:  Sci Rep       Date:  2019-04-23       Impact factor: 4.379

Review 5.  Cytokines and Abnormal Glucose and Lipid Metabolism.

Authors:  Jie Shi; Jiangao Fan; Qing Su; Zhen Yang
Journal:  Front Endocrinol (Lausanne)       Date:  2019-10-30       Impact factor: 5.555

Review 6.  The Effects of Asprosin on Exercise-Intervention in Metabolic Diseases.

Authors:  Lifei Liu; Yuhao Liu; Mei Huang; Miao Zhang; Chenyu Zhu; Xi Chen; Samuel Bennett; Jiake Xu; Jun Zou
Journal:  Front Physiol       Date:  2022-07-11       Impact factor: 4.755

7.  Peripheral CB1 Receptor Neutral Antagonist, AM6545, Ameliorates Hypometabolic Obesity and Improves Adipokine Secretion in Monosodium Glutamate Induced Obese Mice.

Authors:  Haiming Ma; Guina Zhang; Chunrong Mou; Xiujuan Fu; Yadan Chen
Journal:  Front Pharmacol       Date:  2018-03-20       Impact factor: 5.810

8.  Increased serum level and impaired response to glucose fluctuation of asprosin is associated with type 2 diabetes mellitus.

Authors:  Xinyue Zhang; Hui Jiang; Xiaojing Ma; Hongyan Wu
Journal:  J Diabetes Investig       Date:  2019-10-03       Impact factor: 4.232

9.  The role of Asprosin in patients with dilated cardiomyopathy.

Authors:  Ming-Shien Wen; Chao-Yung Wang; Jih-Kai Yeh; Chun-Chi Chen; Ming-Lung Tsai; Ming-Yun Ho; Kuo-Chun Hung; I-Chang Hsieh
Journal:  BMC Cardiovasc Disord       Date:  2020-09-07       Impact factor: 2.298
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.